0
Your Cart
Frequently bought together:
From: Original price was: $ 1.039.00.Current price is: $ 359.99.
From: Original price was: $ 1.049.00.Current price is: $ 179.00.
From: Original price was: $ 999.00.Current price is: $ 199.00.
From: Original price was: $ 849.00.Current price is: $ 99.99.
From: Original price was: $ 1.495.00.Current price is: $ 94.99.
From: Original price was: $ 449.00.Current price is: $ 144.00.
From: Original price was: $ 3.500.00.Current price is: $ 144.00.
From: Original price was: $ 1.399.00.Current price is: $ 149.00.
From: Original price was: $ 1.045.00.Current price is: $ 97.99.
From: Original price was: $ 1.399.00.Current price is: $ 199.99.
Total: $ 166.795.00

UCSF 41st Annual Advances in Heart Disease 2024

December 6–8, 2024 | San Francisco & Virtual

The UCSF 41st Annual Advances in Heart Disease is a premier three-day continuing medical education (CME) course designed for healthcare professionals seeking the latest updates in cardiovascular medicine. Now in its 41st year, this comprehensive program delivers cutting-edge, evidence-based insights to enhance clinical practice and improve patient care.


Key Features

  • Hybrid Format: Attend in person or join live online from anywhere.

  • 30-Day Replay Access: All sessions are recorded and available for on-demand viewing.

  • Expert Faculty: Led by distinguished UCSF cardiologists and national leaders in cardiovascular care.


Course Topics

  • New guidelines and therapies for:

    • Coronary artery disease

    • Heart failure and arrhythmias

    • Lipid and blood pressure management

    • Pulmonary hypertension

    • Diabetes and cardiovascular risk

  • Contemporary issues:

    • GLP-1 agonists and cardiovascular outcomes

    • Mechanical circulatory support

    • Stroke prevention in atrial fibrillation

    • Cardio-renal syndromes

    • Erectile dysfunction and vascular health

    • Diversity in sex- and race-based outcomes


Learning Objectives

Participants will be able to:

  • Apply the latest clinical trial evidence to the management of cardiovascular disease

  • Implement best practices for device therapy, ablation, and structural interventions

  • Integrate risk stratification tools and preventive strategies into daily practice

  • Navigate complex cases involving comorbidities such as diabetes, renal disease, or COVID-19 sequelae

  • Improve diagnostic accuracy in evaluating chest pain, palpitations, and shortness of breath


Target Audience

  • Cardiologists

  • Internists

  • Family physicians

  • Hospitalists

  • Nurse practitioners and physician assistants

  • Fellows-in-training


Accreditation

  • Offers up to 18.75 AMA PRA Category 1 Credits™

  • Suitable for maintenance of certification and licensure requirements

Reviews

There are no reviews yet.

Be the first to review “UCSF 41st Annual Advances in Heart Disease 2024”

Your email address will not be published. Required fields are marked *